Vestronidase Alfa-vjbk Injection (MEPSEVII® )

Covered only for the FDA‑approved indication mucopolysaccharidosis type VII (MPS VII; Sly syndrome); non‑FDA uses are excluded. Requires documentation of deficient beta‑glucuronidase activity (in leukocytes, fibroblasts, or serum) or a GUSB gene mutation and prescription/consultation by a geneticist, endocrinologist, metabolic/lysosomal storage disorder specialist, with dosing 4 mg/kg IV every 2 weeks and approvals limited to 12 months.

"Mepsevii is indicated for the treatment of individuals with mucopolysaccharidosis type VII (MPS VII; Sly syndrome)."

Sign up to see full coverage criteria, indications, and limitations.